Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists.

Trisha Suppes, Susan L. McElroy, Robert Hirschfeld

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

OBJECTIVE: An online survey was conducted to assess psychiatrists' familiarity with the metabolic syndrome and its components in patients with bipolar disorder, and characterize their perspectives and practices regarding its impact on patient management. METHODS: Participants were US psychiatrists from a random sample of those in the AMA database. Qualified respondents practiced 4-30 years, spent > or = 50% of their time in direct patient care, and treated > or = 25 bipolar patients in the last month. Results were collected and tabulated by Harris Interactive from Nov-Dec 2005. RESULTS: Five hundred psychiatrists qualified and completed the survey, and 50 respondents also participated in follow-up interviews. Most respondents (94%) viewed metabolic syndrome as a significant health risk requiring monitoring and treatment.While 76% have diagnosed it, only 28% correctly identified the five NCEP diagnostic criteria. Medication adverse effects of greatest concern were weight gain, glucose intolerance, and dyslipidemia. During treatment, 78% of respondents reported monitoring weight, 69% glucose, 61% lipids, and 52% blood pressure. Most respondents (92%) reported referring patients to specialists or primary care for metabolic abnormalities. Changes in metabolic profile were reported to prompt many psychiatrists (85%) to stop or switch bipolar medications, especially those who treat a large number of bipolar patients (89%). The follow-up interviews supported a change in practice patterns over the last 5 years. CONCLUSIONS: Nearly all respondents have metabolic concerns with medical therapies used to treat bipolar disorder. Many now routinely monitor weight and other metabolic parameters. Most have referred patients for medical management and adjusted bipolar therapies due to metabolic abnormalities.

Original languageEnglish (US)
JournalPsychopharmacology Bulletin
Volume40
Issue number2
StatePublished - 2007

Fingerprint

Bipolar Disorder
Psychiatry
Drug Therapy
Interviews
Weights and Measures
Glucose Intolerance
Metabolome
Surveys and Questionnaires
Therapeutics
Dyslipidemias
Weight Gain
Primary Health Care
Patient Care
Databases
Blood Pressure
Lipids
Glucose
Health

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder : a survey of 500 US psychiatrists. / Suppes, Trisha; McElroy, Susan L.; Hirschfeld, Robert.

In: Psychopharmacology Bulletin, Vol. 40, No. 2, 2007.

Research output: Contribution to journalArticle

@article{d9f3f2ca338645acaa91a2071548ae75,
title = "Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists.",
abstract = "OBJECTIVE: An online survey was conducted to assess psychiatrists' familiarity with the metabolic syndrome and its components in patients with bipolar disorder, and characterize their perspectives and practices regarding its impact on patient management. METHODS: Participants were US psychiatrists from a random sample of those in the AMA database. Qualified respondents practiced 4-30 years, spent > or = 50{\%} of their time in direct patient care, and treated > or = 25 bipolar patients in the last month. Results were collected and tabulated by Harris Interactive from Nov-Dec 2005. RESULTS: Five hundred psychiatrists qualified and completed the survey, and 50 respondents also participated in follow-up interviews. Most respondents (94{\%}) viewed metabolic syndrome as a significant health risk requiring monitoring and treatment.While 76{\%} have diagnosed it, only 28{\%} correctly identified the five NCEP diagnostic criteria. Medication adverse effects of greatest concern were weight gain, glucose intolerance, and dyslipidemia. During treatment, 78{\%} of respondents reported monitoring weight, 69{\%} glucose, 61{\%} lipids, and 52{\%} blood pressure. Most respondents (92{\%}) reported referring patients to specialists or primary care for metabolic abnormalities. Changes in metabolic profile were reported to prompt many psychiatrists (85{\%}) to stop or switch bipolar medications, especially those who treat a large number of bipolar patients (89{\%}). The follow-up interviews supported a change in practice patterns over the last 5 years. CONCLUSIONS: Nearly all respondents have metabolic concerns with medical therapies used to treat bipolar disorder. Many now routinely monitor weight and other metabolic parameters. Most have referred patients for medical management and adjusted bipolar therapies due to metabolic abnormalities.",
author = "Trisha Suppes and McElroy, {Susan L.} and Robert Hirschfeld",
year = "2007",
language = "English (US)",
volume = "40",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "2",

}

TY - JOUR

T1 - Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder

T2 - a survey of 500 US psychiatrists.

AU - Suppes, Trisha

AU - McElroy, Susan L.

AU - Hirschfeld, Robert

PY - 2007

Y1 - 2007

N2 - OBJECTIVE: An online survey was conducted to assess psychiatrists' familiarity with the metabolic syndrome and its components in patients with bipolar disorder, and characterize their perspectives and practices regarding its impact on patient management. METHODS: Participants were US psychiatrists from a random sample of those in the AMA database. Qualified respondents practiced 4-30 years, spent > or = 50% of their time in direct patient care, and treated > or = 25 bipolar patients in the last month. Results were collected and tabulated by Harris Interactive from Nov-Dec 2005. RESULTS: Five hundred psychiatrists qualified and completed the survey, and 50 respondents also participated in follow-up interviews. Most respondents (94%) viewed metabolic syndrome as a significant health risk requiring monitoring and treatment.While 76% have diagnosed it, only 28% correctly identified the five NCEP diagnostic criteria. Medication adverse effects of greatest concern were weight gain, glucose intolerance, and dyslipidemia. During treatment, 78% of respondents reported monitoring weight, 69% glucose, 61% lipids, and 52% blood pressure. Most respondents (92%) reported referring patients to specialists or primary care for metabolic abnormalities. Changes in metabolic profile were reported to prompt many psychiatrists (85%) to stop or switch bipolar medications, especially those who treat a large number of bipolar patients (89%). The follow-up interviews supported a change in practice patterns over the last 5 years. CONCLUSIONS: Nearly all respondents have metabolic concerns with medical therapies used to treat bipolar disorder. Many now routinely monitor weight and other metabolic parameters. Most have referred patients for medical management and adjusted bipolar therapies due to metabolic abnormalities.

AB - OBJECTIVE: An online survey was conducted to assess psychiatrists' familiarity with the metabolic syndrome and its components in patients with bipolar disorder, and characterize their perspectives and practices regarding its impact on patient management. METHODS: Participants were US psychiatrists from a random sample of those in the AMA database. Qualified respondents practiced 4-30 years, spent > or = 50% of their time in direct patient care, and treated > or = 25 bipolar patients in the last month. Results were collected and tabulated by Harris Interactive from Nov-Dec 2005. RESULTS: Five hundred psychiatrists qualified and completed the survey, and 50 respondents also participated in follow-up interviews. Most respondents (94%) viewed metabolic syndrome as a significant health risk requiring monitoring and treatment.While 76% have diagnosed it, only 28% correctly identified the five NCEP diagnostic criteria. Medication adverse effects of greatest concern were weight gain, glucose intolerance, and dyslipidemia. During treatment, 78% of respondents reported monitoring weight, 69% glucose, 61% lipids, and 52% blood pressure. Most respondents (92%) reported referring patients to specialists or primary care for metabolic abnormalities. Changes in metabolic profile were reported to prompt many psychiatrists (85%) to stop or switch bipolar medications, especially those who treat a large number of bipolar patients (89%). The follow-up interviews supported a change in practice patterns over the last 5 years. CONCLUSIONS: Nearly all respondents have metabolic concerns with medical therapies used to treat bipolar disorder. Many now routinely monitor weight and other metabolic parameters. Most have referred patients for medical management and adjusted bipolar therapies due to metabolic abnormalities.

UR - http://www.scopus.com/inward/record.url?scp=34548571967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548571967&partnerID=8YFLogxK

M3 - Article

C2 - 17514184

AN - SCOPUS:34548571967

VL - 40

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 2

ER -